Published on 23/12/2025
How to Calculate KRIs to Monitor Safety and Data Quality in Clinical Trials
Why KRI Calculation Matters in Risk-Based Monitoring
Key Risk Indicators (KRIs) serve as quantitative tools in Risk-Based Monitoring (RBM) that help identify early signals of potential trial issues. For KRIs to be meaningful, their calculations must be accurate, standardized, and reflective of the real risks. Especially for metrics related to patient safety and data quality, flawed computation can mislead decisions, waste resources, or worse—miss critical signals that jeopardize subject well-being.
Regulators such as the FDA, EMA, and ICH emphasize quantitative risk monitoring. This includes calculating metrics such as protocol deviation rate, data entry lag, and SAE reporting timeliness. Understanding how to compute these values systematically enables consistent site evaluation and centralized action.
Key KRIs Focused on Patient Safety
Patient safety-related KRIs are designed to catch delays or gaps in safety monitoring and reporting. Some of the most used metrics include:
- SAE Reporting Lag: Measures the time between Serious Adverse Event (SAE) occurrence and its entry in the Electronic Data Capture (EDC) system.
- AE Reporting Rate: Tracks the number of Adverse Events (AEs) reported per subject or per visit.
- Informed Consent Errors: Identifies issues such
Formulas for Calculating Safety-Related KRIs
| KRI | Formula | Threshold (Example) |
|---|---|---|
| SAE Reporting Lag | (Date of EDC Entry – Date of SAE Onset) | >72 hours |
| AE Reporting Rate | Total AEs / Total Subject Visits | <1 may signal underreporting |
| ICF Error Rate | Number of ICF Errors / Total Consents × 100 | >2% |
| Missed Safety Visits | Number of Missed Safety Visits / Planned Visits × 100 | >5% |
These KRIs should be calculated weekly or monthly depending on the phase of the study. High-risk protocols (e.g., oncology, pediatric) may require more frequent updates.
Common Data Sources and Systems for KRI Computation
To automate KRI calculations, data must be extracted from integrated systems:
- EDC (Electronic Data Capture): Source for AE/SAE dates, query metrics, data entry timestamps
- eTMF: Source for consent documents and protocol versions
- CTMS: Visit schedule, monitoring reports, CRA alerts
- Safety Databases: MedDRA-coded AE/SAE entries and narratives
For GxP-compliant automated calculation templates, you can refer to PharmaSOP.
KRIs Targeting Data Quality
Data quality KRIs are essential for assessing the reliability and integrity of clinical data collected. These metrics allow centralized monitors to pinpoint problematic sites before audit issues arise. Key examples include:
- Data Entry Lag: Delay between site visit date and EDC entry date
- Query Aging: Number of unresolved queries older than a set threshold
- Missing Data Rate: Percentage of CRF fields not filled
- CRF Completion Rate: Measures timeliness and completeness of CRFs
Formulas for Data Quality KRIs
| KRI | Formula | Threshold |
|---|---|---|
| Data Entry Lag | (EDC Entry Date – Visit Date) | >3 Days |
| Query Aging | Queries >14 Days Open / Total Queries × 100 | >10% |
| Missing Data Rate | Blank Fields / Total Fields × 100 | >5% |
| CRF Completion Rate | Completed CRFs / Planned CRFs × 100 | <95% |
For robust implementation, KRIs must be backed by SOPs. PharmaValidation provides example SOPs for RBM KRI integration.
Regulatory Alignment and Inspection Readiness
Health authorities including the FDA and EMA expect KRI calculations to be:
- Clearly defined in Monitoring Plans
- Consistent across sites and studies
- Backed by historical rationale or risk assessments
- Regularly reviewed and trended
During inspections, regulators may request calculation logic, thresholds used, and system validation documents supporting automated KRIs.
Best Practices for KRI Management
- Limit KRIs to those aligned with top study risks
- Use dashboards with visual color alerts
- Establish tiered triggers (green/yellow/red zones)
- Validate formulas in GxP systems
- Ensure CRAs and CTMs are trained in interpretation
Conclusion
KRIs are essential tools for ensuring trial success through data-driven oversight. But their utility depends on accurate, consistent calculation. Patient safety and data quality should be the core focus areas. By applying standard formulas, validating source data, and integrating results into monitoring workflows, clinical teams can respond faster, avoid deviations, and stay audit-ready at all times.